# LUNDINGROUP



**LUNDIN FAMILY** BRAIN TUMOUR RESEARCH CENTRE

# A man who made a difference in this world. Let's continue the journey.

**Lukas' life journey was a remarkable one**. Entrepreneurial, and always adventurous, he was passionate about the resource industry and its power to transform lives. From the high Andes of Argentina to the jungles of Ecuador, he pursued opportunities that led to some of the largest and most successful resource developments in the world.



Argentina **Argentina Gold** Veladero Copper/Gold Project Acquired by Homestake (later acquired by Barrick) Argentina **Lundin Mining** Josemaria Copper-Gold Project

#### Pushing the boundaries of brain cancer research.

His last major initiative was the establishment of the Lundin Family Brain Tumour Research Centre. Let's build upon his legacy.



#### Please join us on this journey.

LUNDIN FAMILY BRAIN TUMOUR RESEARCH CENTRE

**There is no limit on what you can achieve.**– Lukas Lundin

Lukas H. Lundin 1958-2022

Lukas died at the age of 64 from glioblastoma, a form of brain cancer.

# Lundin Family Brain Tumour Research Centre

CHUV University Hospital at Lausanne, Switzerland

#### What Is Glioblastoma?

A rare but very aggressive brain tumour

No known risk factors

Resistant to treatment

### Funding the Very Best in Brain Cancer Research

There is a significant lack of funding and awareness about brain cancer. Lukas' sons, Adam, Jack, William and Harry Lundin, want to honour their father by helping to fund cutting edge research at CHUV, one of the top cancer research hospitals in the world, ultimately allowing for more widely available and effective treatment options. The Lundin family is committed to funding brain cancer research at CHUV over the long term. The work at CHUV is collaborative and any wins in research are shared with hospitals worldwide, allowing exponential growth in those benefits to so many more.

Please join us on this journey to push the boundaries of cancer research innovation.



+

There are over 120 different types of brain tumours, making developing effective treatment very complicated.<sup>1</sup>



Glioblastoma accounts for 49.1 percent of all primary malignant brain tumours.<sup>2</sup>



Average survival rate of Glioblastoma, even with aggressive treatment, is less than one year.<sup>2</sup>



Survival rates and mortality statistics for Glioblastoma have been virtually unchanged for decades.<sup>2</sup>

## About CHUV and the Work They Do.

CHUV is the Lausanne University Hospital in Switzerland. Ranked as one of the top 10 hospitals in the world, it is a leader in brain cancer research and treatment innovation.



CHUV's research will be shared on an international clinical research platform. It is a collaboration with all the research hospitals around the world – including in Canada, U.S., U.K., Europe, etc. – no matter where the donor's money originates from, they will see benefits flow to their home countries.

Lukas chose CHUV because he wanted results as he did from all his investments during his life. It was important for him to know that all stakeholders from around the world would benefit from his legacy investment in brain cancer research.

#### Pushing the Boundaries of Innovation for Brain Tumour Research

Despite the dramatic increase in the number of glioblastoma patients in the past decade and up-to-date treatments, brain tumours, especially glioblastomas, remains a disease with a poor outcome.

To change this pattern, the neurooncology team at CHUV is intensely involved in international and in-house clinical trials. Clinical trials represent an important opportunity for patients to benefit from the latest advances in the field. Over the last 10 years, CHUV has offered over 30 trials for patients with glioblastoma. In 2021 alone, 60% of glioblastoma patients were included in a clinical trial at CHUV. Patients admitted to the CHUV come from Europe, the Middle East, the United States and Russia for treatment. The outpatient consultations at the CHUV have increased from 500 to 2200 per year.

Patients suffering from a brain tumour require specialized care from a large number of specialists. CHUV is one of the few places in the world with highly trained specialists in each of the related fields who are exclusively dedicated to patient care and management through collaboration across disciplines to ensure that patients receive the most up-to-date care.

The clinical trials led by the neurooncology team have resulted in concrete advances in standards of care treatments which are used worldwide today. These breakthrough contributions solidified CHUV's international reputation in this field and led to the creation of the Brain & Spine Tumour Center in 2021, under the direction of Dr. Andreas Hottinger, MD, PhD, FEAN.

# Activities

### Goals

A key objective is to create a ten-year neuro-oncology research platform to discover better treatments for brain tumours.

This research platform will enable a network of centres to coordinate treatment schemes, foster the exchange of ideas between clinicians and biologists, provide cutting-edge translational and clinical research and promote individualized therapy of glioblastoma patients. The platform would also serve as a hub for boosting interactions at the international level.

The goal is to provide brain cancer patients access to the latest knowledge and developments, and to translate and validate the latest preclinical findings into the clinical setting.

Three projects will be launched and led by Lundin Family Brain Tumour Research Centre, which works in partnership and is affiliated with the Department of Oncology and the Department of Clinical Neurosciences of the Lausanne University Hospital:

## Engineering T cell therapies

Chimeric Antigen Receptor T (CAR T) cells can be used to boost the patient's own immune system against the glioblastoma and holds great promise for patients. The goal is to design tailored CAR T cells against multiple glioblastoma antigens targeting the whole tumour cell population of the patient's tumour.

#### Disrupting the blood brain barrier (BBB) to treat brain tumours

The BBB protects the brain from toxic elements but also prevents potential drugs from penetrating the brain tissue. Finding ways to improve the diffusion of agents may improve the outcome of patients with brain tumours.

# Launching a clinical trial platform

The aim of this infrastructure is to test new drugs in recurrent glioblastoma. Patient tumour specimens would be characterized and screened to determine drug alternatives. Patients considered for reoperation would be offered a targeted treatment agent shortly before repeat surgery and to be continued until further tumour progression.

### Lundin Family Brain Tumour Research Centre **How will the funds raised be used**

#### Innovation

Push innovation boundaries in Neuro-Oncology



### **Clinical Trials**

Clinical trials represent an important opportunity for patients to benefit from the latest advances in the field

### **Expansion**

Expanding the Brain & Spine Tumour Centre activity from preclinical to clinical research

### Neuro-Oncology Research Platform

Network of centres to coordinate treatment schemes, foster exchange of ideas between clinicians and biologists, provide cutting edge translational and clinical research and promote individualized therapy for brain cancer patients

### Top Three Clinical Trial Projects

Engineering T cell therapies

Disrupting the blood brain barrier (BBB) to treat brain tumours

Launching a clinical trial platform

#### Collaboration

Local and international collaborations in neuro-oncology

#### Research

Push the boundaries of knowledge and accelerate the development of solutions



# The journey continues.

# Lukas' life journey was a truly remarkable one.

We want to honour Lukas by helping to fund cutting edge research at one of the top cancer research hospitals in the world, ultimately allowing for more widely available and effective treatment options around the world. Lundin Family Committed to Funding Brain Cancer Research Over the Long Term

Lukas' sons, Jack, William, Adam and Harry, would like to work with his friends and colleagues to build upon and carry forward this important legacy.

The CHUV funding initiative and climbing Mount Everest to raise awareness of brain cancer are all in honour of their dad.



William, Jack, Harry and Adam Lundin

### **Project No Limit**

To bring more awareness and publicity to funding brain cancer research, Jack and William Lundin are embarking on a momentous journey of their own.

In the Spring of 2023, they will be climbing Mount Everest guided by Nirmal Purja. Every step of the journey will be in honour of their dad.

The climb will be filmed and made into a documentary about Lukas' inspiring life. The working title of the film is "No Limits". See <a href="http://www.thelundingroup.com">www.thelundingroup.com</a> to view a trailer.

The Mount Everest climb is part of a multi component plan to raise funds and awareness for brain cancer research.





Lukas Lundin

Our goal is to make a high impact investment in brain cancer research that significantly benefits patients and for them to know that they are not alone in their fight.

### Please join us on this journey.

The Lundin Family are committed to raising awareness and funding to help advance brain cancer research in a meaningful way.

By donating to the Lundin Family Brain Tumour Research Center, you are helping to carry on Lukas' legacy and push the boundaries of brain cancer research.

Thank you. We appreciate your support.

### **LUNDIN FAMILY** BRAIN TUMOUR RESEARCH CENTRE

### How to donate:

Official tax receipts issued.

#### USA

kbfus.networkforgood.com/projects/54524-f-kbfus-funds-fondation-chuv-ch

#### CANADA

www.kbfcanada.ca/en/projects/pushing-the-boundaries-of-innovation-for-braintumor-research/

#### SWITZERLAND & OTHER COUNTRIES:

www.lausanneuniversityhospital.com/pushing-the-boundaries-of-innovation-forbrain-tumor-research Please write Lukas Lundin in the box labelled Motif du Don

#### OR VIA WIRE TRANSFER:

Fondation CHUV (in memory of Lukas Lundin) Banque Cantonale Vaudoise IBAN: CH14 0076 7000 T525 3600 1 BIC: BCVLCH2LXXX Clearing: 767

For further information on how you can help support brain cancer research, please contact: Sophia Shane The Lundin Group Mb. +1 604 306 6867 sophias@namdo.com thelundingroup.com

